B7 costimulatory ligand regulates development of the T-cell response to Cryptococcus neoformans

Immunology

Volumn 98, Issue 1, 1999, Pages 27-35

  Monari, C ^a   Kozel, T R ^b   Casadevall, A ^c   Pietrella, D ^a   Palazzetti, B ^a   Vecchiarelli, A ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTING CELL; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGUS GROWTH; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATORY CELL; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CRYPTOCOCCUS NEOFORMANS; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; POLYSACCHARIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TH1 CELLS;

EID: 0032836547     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1999.00853.x     Document Type: Article

References (38)

1. 1. KWONG-CHUNG K.J. & BENNETT J.E. (1992) Medical mycology, pp. 397. Lea and Febinger, Malvern, PA.
2. 2. CHERNIAK R. & SUNDSTROM J.B. (1994) Polysaccharide antigens of the capsule of Cryptoroccus neoformans. Infect Immun 62, 1507.
3. 3. KOZEL T.R. & GOTSCHLICH E. (1982) The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast macrophages. J Immunol 129, 1675.
4. 4. VECCHIARELLI A., DOTTORINI M., PIETRELLA D. et al. (1994) Role of alveolar macrophages as antigen presenting cells in Cryptococcus neoformans infection. Am J Respir Cell Mol Biol 11, 130.
5. 5. VECCHIARELLI A., PIETRELLA D., DOTTORINI M. et al. (1994) Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol 98, 217.
6. 6. RETINI C., VECCHIARELLI A., MONAKI C., BISTONI F. & KOZEL T.R. (1998) Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect Immun 66, 664.
7. 7. VECCHIARELLI A., RETINI C., MONARI C. & CASADEVALI A. (1998) Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation. Infect Immun 66, 1244.
8. 8. VAN GOOL S.W., VANDENBERGHE P., DE BOER M. & CEUPPENS J.L. (1996) CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev 153, 47.
9. 9. SCHWARTZ R.H. (1990) A cell culture model for T lymphocyte clonal anergy. Science 248, 1349.
10. 10. NATESAN M., RAZI-WOLF Z. & REISER H. (1996) Costimulation of IL-4 production by murine B7-1 and B7-2 molecules. J Immunol 156, 2783.
11. + T cells induce similar patterns of cytokine secretion in vitro. Int Immunol 7, 891.
12. 12. FREEMAN G.J., BOUSSIOTIS V.A., ANUMANTHAN A, et al. (1995) B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2, 523.
13. 13. RANGER A.M., DAS M.P., KUCHROO V.K. & GLIMCHER L.H. (1996) B7-2 (CD86) is essential for the development of interleukin-4 producing T cells. Int Immunol 8 (Suppl. 10), 1549.
14. 2 development pathways: application to autoimmune disease therapy. Cell 80, 707.
15. 15. RACKE M.K., SCOTT D.E., QUIGLEY L. et al. (1995) Distinct roles for B7-1 (CD80) and B7-2 (CD86): in the initiation of experimental allergic encephalomyelitis. J Clin Invest 96, 2195.
16. 16. LENSCHOW D.J., HO S.C., SATTAR H. et al. (1995) Differential effect of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 181, 1145.
17. 17. VECCHIARELLI A., MONARI C., RETINI C. et al. (1998) Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86): expression on human monocytcs. Eur J Immunol 28, 114.
18. 18. CASADEVALL A., MUKHERJEE J., DEVI S.J.N., SCHNEERSON R., ROBBINS J.B. & SCHARFF M.D. (1992) Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis 65, 1086.
19. 19. CHERNIAK R., REISS E. & TURNER S.H. (1982) A galactoxylomannan antigen of Cryptococcus neoformans serotype A. Carbohydr Res 103, 239.
20. 20. CHERNIAK R., REISS E., SLODKI M.E., PLATTNER R.D. & BLUMER S.O. (1980) Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans. Mol Immunol 17, 1025.
21. 21. MONARI C., RETINI C., PALAZZETTI B., BISTONI F. & VECCHIARELLI A. (1997) Regulatory role of exogenous IL-10 in the development of immune response versus Cryptococceus neoformans. Clin Exp Immunol 109, 242.
22. 22. CELLA M., ENGERING A., PINET V., PIETERS J. & LANZAVECCHIA A. (1997) Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388, 782.
23. 23. NETEA M.G., DRENTH J.P.H., DE BONT N. et al. (1996) A semi-quantitative reverse transcriptase polymerase chain reaction method for measurement of mRNA for TNF-α and IL-1β in whole blood cultures: its application in typhoid fever and exentric exercise. Cytokine 8, 739.
24. 24. MUKHERJEE J., SCHARFF M.D. & CASADEVALL A. (1992) Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 60, 4534.
25. 25. CASADEVALL A. (1995) Antibody immunity and invasive fungal infections. Infect Immun 63, 4211.
26. 26. FELDMESSER M., KRESS Y. & CASADEVALL A. (1998) Effect of antibody to capsular polysaccharide on cosinophilic pneumonia in murine infection with Cryptococcus neoformans. J Infect Dis 177, 1639.
27. 27. RETINI C., CASADEVALL A., PIETRELLA D., MONARI C., PALAZZETTI B. & VECCHIARELLI A. (1999) Specific activated T cells regulate interleukin-12 production by human monocytes stimulated with Cryptococcus neoformans. J Immunol 162, 1618.
28. 28. LARSEN C.P., RITCHIE S.C., HENDRIX R. et al. (1994) Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 152, 5208.
29. 29. OHTANI H., NAITO Y., SAITO K. & NAGURA H. (1997) Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: a possible antitumor immunity? Lab Invest 77, 231.
30. 30. MCCOY K., CAMBERIS M. & LE GROS G. (1997) Protective immunity to nematode infection is induced by CTLA-4 blockade. J Exp Med 186, 183.
31. 31. FROSCH S., KUNTZLIN D. & FLEISCHER B. (1997) Infection with Trypanosoma cruzi selectively upregulates B7-2 molecules on macrophages and enhances their costimulatory activity. Infect Immun 65, 971.
32. 32. DAIKH D., WOSFY D. & IMBODIN J.B. (1997) The CD28 B7 costimulatory pathway and its role in autoimmune disease. J Leukoc Biol 62, 156.
33. 33. CREERY W.D., DIAZ-MITOMA F., FILION L. & KUMAR A. (1996) Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Eur J Immunol 26, 1273.
34. 34. NAKAJIMA A., WATANABE N., YOSHINO S., YAGITA H., OKUMUKA K. & AZUMA M. (1997) Requirement of CD28 CD86 co-stimulation in the interaction between antigen-primed T helper type 2 and B cells. Int Immunol 9 (Suppl. 5), 637.
35. 35. HOAG K.D., LIPSCOMB M.F., IZZO A.A. & STREET N.E. (1997) IL-12 and IFN-γ are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am J Respir Cell Biol 17, 733.
36. 36. DE LA SALLE H., GALON J., BAUSINGER H. et al. (1997) Soluble CD16/Fc gamma RIII induces maturation of dendritic cells and production of several cytokines including IL-12, Adv Exp Med Biol 417, 345.
37. 37. WOODROOFE M.N., HAYES G.M. & CUZNER M.L. (1989) Fc receptor density, MHC antigen expression and Superoxide production are increased in interferon-gamma-treated microglia isolated from adult rat brain. Immunology 68, 421.
38. 38. FEILDMESSER M. & CASADEVALL A. (1997) Effect of serum IgG1 against murine pulmonary infection with Cryptococcus neoformans. J Immunol 158, 790.